These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 5289696)
1. Phagocytosis-promoting effect of clofazimine (B 663) in patients with subnormal granulocyte function. Brandt L Scand J Haematol; 1971; 8(5):400-4. PubMed ID: 5289696 [No Abstract] [Full Text] [Related]
2. Reduced number of peripheral blood granulocytes in chronic myeloid leukaemia during administration of clofazimine (B 663). Brandt L Scand J Haematol; 1972; 9(2):159-66. PubMed ID: 4504500 [No Abstract] [Full Text] [Related]
3. Enhancing effect of clofazimine (B663) on the phagocytosis of neutrophilic leucocytes in vitro. Brandt L Scand J Haematol; 1971; 8(4):265-9. PubMed ID: 5289665 [No Abstract] [Full Text] [Related]
4. Syndrome of anaemia, thrombocytopenia and subnormal granulocyte function in elderly patients. Berg B; Brandt L Scand J Haematol; 1973; 10(3):161-9. PubMed ID: 4520465 [No Abstract] [Full Text] [Related]
5. Clofazimine therapy of lepromatous leprosy caused by dapsone-resistant mycobacterium leprae. Levy L; Shepard CC; Fasal P Am J Trop Med Hyg; 1972 May; 21(3):315-21. PubMed ID: 4554496 [No Abstract] [Full Text] [Related]
6. [Experimental studies in man on hyaluronidase inhibiting effect of clofazimine]. Mathies H; Ress U Arzneimittelforschung; 1970 Dec; 20(12):1838-40. PubMed ID: 5537076 [No Abstract] [Full Text] [Related]
8. Bacteriological effect of Lamprene (clofazimine) in lepromatous leprosy (report of one year's treatment of 44 patients with 100 mg of Lamprene daily). Leiker DL; Blenska W; Carling D; Fitzherbert M; Larssen P Lepr Rev; 1971 Jun; 42(2):125-30. PubMed ID: 4948481 [No Abstract] [Full Text] [Related]
9. The use of B 663 (clofazimine) in the treatment of Chinese leprosy patients with chronic reaction. Warren AG Lepr Rev; 1970 Apr; 41(2):74-82. PubMed ID: 5453082 [No Abstract] [Full Text] [Related]
10. Treatment of leprosy with a phenazine derivative (B 663 or G 30 320)--clofazimine. Gatti JC; Cardama JE; Balina LM; Crespi HG; Bianchi O; Santabaya E; Farina MH Lepr Rev; 1970 Apr; 41(2):89-92. PubMed ID: 5453084 [No Abstract] [Full Text] [Related]
11. Clofazimine in leprosy. Browne SG Br Med J; 1972 Feb; 1(5798):506-7. PubMed ID: 4550304 [No Abstract] [Full Text] [Related]
12. Clofazimine in leprosy. Schulz EJ Br Med J; 1972 Mar; 1(5802):749. PubMed ID: 5015339 [No Abstract] [Full Text] [Related]
13. [Trial of a new leprostatics (B-663) in the treatment of lepromatous leprosy]. Renders A Ann Soc Belges Med Trop Parasitol Mycol; 1968; 48(6):625-35. PubMed ID: 5759964 [No Abstract] [Full Text] [Related]
14. The antileprosy agent B.663 (Clofazimine) and the reticuloendothelial system. Conalty ML; Barry VC; Jina A Int J Lepr Other Mycobact Dis; 1971; 39(2):479-92. PubMed ID: 4948088 [No Abstract] [Full Text] [Related]
15. Activity of phenazine analogs against Mycobacterium leprae infections in mice. Van Landingham RM; Walker LL; O'Sullivan JF; Shinnick TM Int J Lepr Other Mycobact Dis; 1993 Sep; 61(3):406-14. PubMed ID: 8228439 [TBL] [Abstract][Full Text] [Related]
16. Double-blind controlled clinical trial of clofazimine in reactive phases of lepromatous leprosy. Karat AB; Jeevaratnam A; Karat S; Rao PS Br Med J; 1970 Jan; 1(5690):198-200. PubMed ID: 4904935 [TBL] [Abstract][Full Text] [Related]